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Abstract
In this systematic review, we estimated the total number of episodes of bloodstream infection (BSI) and deaths from BSI per year in North
America and Europe, using data from population-based settings. Then, we estimated the number of episodes and deaths from nosocomial
BSI from population-based studies and nosocomial infection surveillance systems. We estimated 575 000–677 000 episodes of BSI per year
in North America (536 000–628 000 in the USA and 40 000–49 000 in Canada) and 79 000–94 000 deaths (72 000–85 000 in the USA
and 7000–9000 in Canada), using estimates from three population-based studies. We estimated over 1 200 000 episodes of BSI and
157 000 deaths per year in Europe, using estimates from one population-based study in each of the following countries: Denmark (9100
episodes and 1900 deaths), Finland (8700 episodes and 1100 deaths) and England (96 000 episodes and 12 000–19 000 deaths). There
were substantial differences in estimates of nosocomial BSI between population-based and nosocomial infection surveillance data. BSI has a
major impact on the morbidity and mortality of the general population, as it ranks among the top seven causes of death in all included
countries in North America and Europe. However, it is difficult to obtain precise estimates of nosocomial BSI, owing to the limited number
of studies. This review highlights the need for a greater focus on BSI research in order to reduce the overall burden of disease by improving
the outcome of patients with BSI. It also emphasizes the role of infection control and prevention methods in reducing the burden of
nosocomial BSI.
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Introduction
Despite the great advances in medical science in the past
century, bloodstream infection (BSI) remains a growing public
health concern in the modern world. It is ranked as the 11th
leading cause of death in the USA, accounting for nearly 36 000
deaths in 2008 [1]. However,we believe that the burden of BSI as
measured by the International Statistical Classification of
Diseases and Related Health Problems (ICD) is underestimated.
Many cases of BSI may, rather, be coded according to the
underlying source of infection. For example, patients with BSI
secondary to urinary, respiratory or gastrointestinal tract
sources of infection may be assigned diagnostic codes for
urinary tract infection, pneumonia, or peritonitis, respectively.
Additionally, BSI may be overlooked as a cause of death,
particularly in patients with terminal medical conditions, such as
advanced malignancy or end-stage kidney or liver disease.
In this systematic review, we aimed to estimate the overall
burden of BSI in countries where the incidence rate of BSI has
been established in population-based settings. As population-
based studies provide data about local residents from all
microbiology laboratories within the specified geographical
area, we expected those studies to provide more accurate
figures than those based on ICD codes. We focused on
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nosocomial BSI, because these cases are potentially prevent-
able with adequate infection control measures within local
hospitals. We used two different methods to estimate the
burden of nosocomial BSI. First, we estimated the burden of
nosocomial BSI from population-based studies. Then, we used
nosocomial infection surveillance systems to estimate the
burden of nosocomial BSI in countries where such systems
were available. We limited this report to North America and
Europe, because it was difficult to obtain estimates from other
parts of the world, owing to a lack of population-based studies
that included all cases of BSI from well-defined geographical
areas.
Methods
Estimates of total burden of BSI from population-based
studies
We examined population-based studies that extended beyond
the year 2000 and reported the incidence rate of BSI in well-
defined geographical areas. The number of episodes of BSI in
each country was calculated as the age-adjusted and gender-
adjusted incidence rate of BSI per 100 000 person-
years 9 population in millions 9 10. We used the average
incidence rate of BSI if the incidence rate was stable
throughout the study period, or the incidence rate during
the most recent interval of the study if there was a temporal
change in incidence rate. In order to estimate the total number
of episodes of BSI in countries where the incidence rate was
reported in a small geographical area within the nation, we
used the upper and lower limits of the 95% confidence
intervals (CI) of the incidence rate age-adjusted and gender-
adjusted to the national population. The population of each
country was obtained from the most recent census results or
projected population estimates as available.
In countries where the mortality rate of BSI was reported in
population-based studies, we calculated the number of deaths
as mortality rate per 100 000 person-years 9 population in
millions 9 10. When the BSI mortality rate was not reported,
we used the short-term (14-day, 28-day, 30-day or in-hospital)
case-fatality rate (CFR) of BSI as reported from population-
based studies that extended beyond the year 2000 in that
nation to calculate the total number of deaths following BSI in
each country. In countries where no studies reporting the
overall BSI CFR were available, we used a wide range for CFR
as estimated from studies in other North American and
European counties. The number of deaths was calculated as
the number of episodes of BSI 9 proportion of CFR. We
calculated BSI mortality rate by multiplying the incidence rate
of BSI by CFR proportion.
Estimates of burden of nosocomial BSI from population-
based studies
Nosocomial BSI was defined as BSI acquired 48 h after hospital
admission. The number of episodes of nosocomial BSI was
calculated as total number of episodes of BSI 9 proportion of
nosocomial BSI from all cases as reported from population-
based studies in each country. Then, we used the CFR of
nosocomial BSI as reported from either population-based or
institutional studies that extended beyond the year 2000 to
calculate the total number of deaths following nosocomial BSI
in each country. We used a range for CFR in nations where
more than one study was found. The number of deaths was
calculated as the number of episodes of nosocomial
BSI 9 proportion of CFR.
Estimates of burden of nosocomial BSI from nosocomial
infection surveillance systems
We used a different approach to evaluate the burden of
nosocomial BSI. We estimated the number of episodes of
nosocomial BSI annually on the basis of surveillance studies of
nosocomial infections. Nationwide surveillance systems that
track the incidence rate of nosocomial infections are imple-
mented in many North American and European countries.
These surveillance systems estimate attack rates of nosocomial
infections, including BSI, in hospitalized patients. The advanta-
ges of a nationwide surveillance system over an institutional
study of nosocomial BSI include heterogeneity of sampling
hospitals, a wide geographical catchment area, and a large
number of participating facilities. However, most surveillance
programmes are focused on a proportion of nosocomial BSI
with more public health interest, such as central-line-associ-
ated BSI or infections caused by multidrug-resistant organisms.
The number of episodes of nosocomial BSI was calculated as
the incidence rate of nosocomial BSI per 1000 hospital
admissions 9 annual number of hospital admissions in each
country as reported by the Organization for Economic Co-
operation and Development/1000 [2,3]. Then, we used the
same methods as above to calculate the number of deaths
from nosocomial BSI.
Results
Estimates of total burden of BSI from population-based
studies
North America. The most recent population-based study of BSI
in the USA was conducted in Olmsted County, Minnesota,
from 2003 to 2005, and estimated an age-adjusted and gender-
adjusted incidence rate of 189 (95% CI 174–204) per 100 000
person-years [4]. Given a USA population of 308 million in
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2010 (US Census Bureau (http://quickfacts.census.gov),
accessed 1 October 2012), we estimated approximately
582 000 episodes of BSI per year in the USA. The annual
number of episodes of BSI in the USA probably fell between
536 000 and 628 000, according to the upper and lower limits
of the 95% CI of the age-adjusted and gender-adjusted
incidence rate, respectively (Table 1).
The same population-based study reported an in-hospital
CFR of BSI of 13.5% [4]. This was similar to the in-hospital CFR
of 13% recently reported from a large multicentre study from
59 hospitals in the USA [5] and the in-hospital-attributable
CFR of 12% in another recent large multicentre study [6], as
summarized in Table 2. On the basis of a CFR of 13.5%, we
estimated that 72 000–85 000 individuals die each year in the
USA shortly following an episode of BSI. This corresponded to
a mortality rate of 23–28 per 100 000 person-years. Accord-
ingly, we concluded that BSI was the seventh most common
cause of death and the leading cause of death caused by
infections in the USA [1].
In Canada (population of nearly 35 million), the incidence
rates of community-onset BSI were 81.6 and 101.2 per
100 000 person-years, in the Calgary and Victoria areas,
respectively [7,8]. Accordingly, we estimated nearly 28 000–
35 000 episodes per year of community-onset BSI in Canada.
However, these estimates represent only 72% of the total
episodes of BSI in Canada, as another population-based study
performed in Calgary showed that 28% of all episodes of BSI
were acquired in the hospital [9]. After accounting for
nosocomial cases, we estimated nearly 40 000–49 000 total
episodes of BSI per year in Canada. The in-hospital CFR of BSI
in Calgary was 18% [9]. Accordingly, we estimated 7000–9000
deaths per year following BSI in Canada, with a mortality rate
of 20–25 per 100 000 person-years, making BSI the sixth
leading cause of death in Canada and the leading cause of
deaths caused by infections (Statistics Canada (www.statcan.
gc.ca), accessed 24 January 2013).
On the basis of these calculations from the USA and
Canada, we estimated nearly 575 000–677 000 episodes of BSI
TABLE 1. Overall burden of bloodstream infection (BSI) in North America and Europe
Country/Region
Population
(in millions)
Incidence rate of
BSI (per 100 000
person-years)
Estimated annual
number of episodes
of BSI
Short-term
case-fatality
rate following
BSI (%)
Estimated
mortality
rate of BSI
(per 100 000
person-years)
Estimated annual
number of deaths
following BSI
USA 308.0 174–204a 535 920–628 320 13.5 23.5–27.5 72 349–84 823
Canada 34.9 113.3–140.6b 39 542–49 069 18 20.4–25.3 7117–8832
North America 342.9 – 575 462–677 389c – – 79 466–93 655c
Denmark 5.5 166 9130 20.6 34.2 1881
Finland 5.2 168 8736 13 22 1144
England 50.8 189 96 012 13–20d 24.6–37.8 12 482–19 202
Europe 731.0 166–189d 1 213 460–1 381 590 13–20d 21.6–37.8 157 750–276 318
aNinety-five per cent CIs of the incidence rate age-adjusted and gender-adjusted from Olmsted County, Minnesota to the US white population.
bThe incidence rate was calculated on the basis of incidence rates of community-onset BSI of 81.6 and 101.2 per 100 000 person-years in the Calgary and Victoria regions,
respectively, on the assumption that 28% of all episodes were nosocomial.
cThe annual number of episodes and deaths from BSI in North America were calculated by adding the numbers from the USA and Canada.
dEstimates are based on results from population-based studies in other European countries.
TABLE 2. Summary of recent studies reporting case-fatality rates of bloodstream infection (BSI) in North America and Europe
Country Years Type of study Setting
Number of
participating
hospitals
Number of
episodes of
BSI
Case-
fatality
rate (%) Type of case fatality
First author
[reference]
USA 2003–2005 Population-based Regional
(Olmsted County,
Minnesota)
2 650 13.5 In-hospital, all-cause (crude) Uslan [4]
USA 2002–2003 Multicentre,
retrospective
Multiple settings 59 6697 13 In-hospital, all-cause (crude) Shorr [5]
USA 2004 Multicentre,
retrospective
Academic
medical centres
3 1225 12 In-hospital, attributable Pien [6]
Canada 2000–2007 Population-based Regional (Calgary) 3 7712 18 In-hospital, all-cause (crude) Lenz [9]
Denmark 1992–2006 Population-based Regional
(northern Denmark)
8–11 14 303 20.6a 30-day all-cause (crude) Sogaard [10]
Finland 2004–2007 Population-based Nationwide NA 33 473 13 30-day all-cause (crude) Skogberg [11]
Spain 2003–2004 Multicentre,
prospective,
observational
Academic
medical centres
3 1157 18.5 30-day all-cause (crude) Valles [20]
NA, not available.
aCase-fatality rate during the 2002–2006 period of the study.
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and 79 000–94 000 deaths per year shortly following BSI in
North America.
Europe. In Denmark (population of 5.5 million in 2006), the
incidence rate of BSI increased over a period of 15 years to
reach an age-adjusted and gender-adjusted incidence rate of
166 per 100 000 person-years in 2006 in a population-based
study in northern Denmark [10]. This corresponded to a total
of nearly 9000 episodes of BSI in Denmark in 2006. The 30-day
CFR following BSI was 20.6% during the 2002–2006 period of
the same study [10]. Therefore, we estimated nearly 1900
deaths from BSI per year in Denmark. BSI was the seventh
leading cause of death in Denmark in 2006 (StatBank Denmark
(http://statbank.dk), accessed 1 October 2012).
Finland has a similar population as Denmark (5.2 million).
The age-adjusted and gender-adjusted incidence rate of BSI
was 168 per 100 000 person-years in a population-based study
that included all cases of BSI in Finland in 2007 [11]. From that,
we estimated a total of nearly 8700 episodes of BSI per year in
Finland. The study provided direct examination of the
mortality rate within 30 days of BSI in the Finish population,
which was 22 per 100 000 person-years [11]. As a result, we
estimated nearly 1100 deaths from BSI per year in Finland. On
the basis of these estimates, BSI would be the seventh leading
cause of death in Finland (Statistics Finland (http://stat.fi),
accessed 1 October 2012).
In England (population of 50.8 million), the incidence rate of
BSI in 2008 was 189 per 100 000 person-years [12]. We
estimated a total of nearly 96 000 episodes of BSI per year.
There was no direct examination of the CFR of BSI in England
in population-based settings. Therefore, we used a wide range
for the CFR of 13–20%, which yielded 12 000–19 000 deaths
following BSI each year in England. This made BSI the fifth
leading cause of death in England, and the leading cause of
death caused by infections, according to the most conservative
estimates (Office for National Statistics (www.ons.gov.uk),
accessed 1 October 2012).
Estimation of the total number of episodes of BSI in
Europe was difficult, owing to the lack of population-based
studies in most other European countries. However, when
we applied a range for the incidence rate of 166–189 per
100 000 person-years extrapolated from population-based
studies in Denmark, Finland and England [10–12] to the entire
population of Europe of 731 million as estimated in 2007
(United Nations, World Population Prospects (www.un.org),
accessed 1 October 2012), we estimated 1.2–1.4 million
episodes of BSI per year in Europe. The use of a CFR range of
13–20% derived from population-based studies in Europe
[10,11] yielded 158 000–276 000 deaths following BSI per
year in Europe.
Estimates of the burden of nosocomial BSI from population-
based studies
North America. In the USA, 19.1% of the total episodes of BSI
were nosocomial in population-based settings [4]. On the
basis of this, we estimated 102 000–120 000 episodes of
nosocomial BSI per year in the USA (Table 3). To our
knowledge, the CFR of nosocomial BSI has not been reported
from population-based studies in the USA that examined all
episodes of BSI. Recent multicentre studies from the USA
have reported a CFR of 15–30%, as summarized in Table 4
[5,13,14]. On the basis of this wide range, we estimated
15 000–36 000 deaths following nosocomial BSI in the USA
per year.
Population-based studies in Canada demonstrated that 28%
of BSI episodes were nosocomial [9]. This corresponded to
11 000–14 000 episodes of nosocomial BSI per year, based on
estimates from the Calgary and Victoria areas [7,8]. On the
basis of a CFR of 26% that was recently reported in a
population-based study in Calgary [9], we estimated 2900–
3600 deaths following nosocomial BSI in Canada per year.
On the basis of the above figures in the USA and Canada,
we estimated 113 000–134 000 episodes of nosocomial BSI
and 18 000–40 000 deaths per year in North America.
TABLE 3. Burden of nosocomial bloodstream infection (BSI) in North America and Europe as estimated from population-based
studies
Country/Region
Estimated annual number
of episodes of BSI
Proportion of
nosocomial
episodes (%)
Estimated annual
number of episodes
of nosocomial BSI
Case-fatality
rate following
nosocomial BSI (%)
Estimated annual
number of deaths
following nosocomial BSI
USA 535 920–628 320 19.1 102 361–120 009 15–30 15 354–36 003
Canada 39 542–49 069 28 11 072–13 739 26 2879–3572
North America 575 462–677 389a – 113 433–133 748a – 18 233–39 575a
Denmark 9130 35 3196 27.6 882
Finland 8736 20–30b 1747–2621 16 280–419
England 96 012 20–30b 19 202–28 804 12–32b 2304–9217
Europe 1 213 460–1 381 590 20–30b 242 692–414 477 12–32b 29 123–132 633
aThe annual number of episodes and deaths following nosocomial BSI in North America was calculated by adding the numbers from the USA and Canada.
bEstimates are based on results from studies in other countries in North America and Europe.
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Europe. In Denmark, 35% of episodes of BSI were hospital-
acquired between 2002 and 2006 [10]. Accordingly, we
estimated 3200 episodes of nosocomial BSI per year during
that period. On the basis of a 30-day CFR of 27.6% [10], we
estimated nearly 900 deaths per year from nosocomial BSI.
The proportions of episodes of nosocomial BSI were not
reported in population-based studies from Finland and England.
Therefore, we used a 20–30% estimate for the proportion of
nosocomial BSI among all episodes. Accordingly, we estimated
1700–2600 and 19 000–29 000 episodes of nosocomial BSI
per year in Finland and England, respectively. On the basis of a
CFR of nosocomial BSI in Finland of 16% [15], we estimated
300–400 deaths following nosocomial BSI per year in Finland.
There were no direct estimates of the CFR of nosocomial BSI
from England; therefore, we used a wide range of 12–32%,
based on results from other European countries, as summa-
rized in Table 4 [15–20]. This yielded a wide range of 2000–
9000 deaths per year.
When we applied the same figures (20–30% of nosocomial
BSI among all episodes and 12–32% CFR) to the entire
population of Europe, we estimated over 240 000 episodes of
nosocomial BSI and 29 000 deaths per year.
Estimates of burden of nosocomial BSI from nosocomial
infection surveillance systems
North America. To estimate the nationwide incidence of noso-
comial BSI, the Surveillance and Control of Pathogens of
Epidemiological Importance (SCOPE) study was conducted
from 1995 to 2002 [13]. The study enrolled 49 hospitals of
various sizes with a wide geographical distribution, and detected
24 179 cases of nosocomial BSI (approximately 6.0 cases per
1000 hospital admissions or 0.8 cases per 1000 patient-days).On
the basis of nationwide hospital discharge data of 37 804 021
discharges in the USA in 2002 (US Department of Health and
Human Services (http://hcupnet.ahrq.gov), accessed 20 Septem-
ber 2012), we estimated approximately 227 000 episodes of
nosocomial BSI per year in the USA (Table 5). We estimated
34 000–68 000deaths per year fromnosocomial BSI in theUSA,
based on aCFRof 15–30% as derived fromother nosocomial BSI
studies in the USA (Table 4).
Europe. France conducted a nationwide surveillance of noso-
comial BSI from 2002 to 2004, as a part of the RAISIN (Reseau
d’alerte, d’investigation et de surveillance des infections
nosocomiales) network [18]. In 2004, the programme
reported an incidence rate of 0.45 per 1000 patient-days. As
the average hospital stay for all causes in France has been
stable at approximately 6 days throughout the 2000s [2], these
data were converted to 2.7 per 1000 hospital admissions. On
the basis of the total population of 62.7 million (World Bank
(http://www.worldbank.org), accessed 24 October 2012) and
annual hospital discharges of 263 per 1000 population in 2004
[2], we estimated approximately 45 000 episodes of nosoco-
mial BSI per year. When we utilized a CFR of 12% [18], the
annual number of deaths from nosocomial BSI in France was
nearly 5500.
The Nosocomial Infection National Surveillance Service of
the UK also conducted a surveillance of nosocomial BSI
TABLE 4. Summary of recent reports of case-fatality rates of nosocomial bloodstream infection (BSI) in North America and
Europe.
Country Years Type of study Setting
Number of
participating
hospitals
Number of
episodes of
nosocomial
BSI
Case-
fatality
rate (%)
Type of case
fatality
First author
[reference]
USA 1995–2002 Multicentre, prospective,
observational
Multiple
settings
49 24 179 27 In-hospital,
all-cause (crude)
Wisplinghoff [13]
USA 2000–2001 Multicentre, prospective,
observational
Multiple
settings
3 175 30 In-hospital,
all-cause (crude)
Freedman [14]
USA 2002–2003 Multicentre, retrospective Multiple
settings
59 468 15 In-hospital,
all-cause (crude)
Shorr [5]
Canada 2000–2007 Population-based,
surveillance
Regional
(Calgary)
3 2132 26 28-day all-cause
(crude)
Lenz [9]
Belgium 2003 Surveillance Nationwide 19 1839 31.8 In-hospital,
all-cause (crude)
Vrijens [16]
Estonia 2004–2005 Multicentre, prospective
observational
Multiple
settings
3 549 31 In-hospital,
all-cause (crude)
Mitt [17]
Finland 1999–2000 Multicenter, prospective,
observational
Multiple
settings
4 1477 16 30-day
all-cause (crude)
Lyytikainen [15]
France 2004 Surveillance report Nationwide 286 4548 12 7-day
all-cause (crude)
RAISIN [18]
Spain 2006–2007 Multicentre, prospective,
surveillance
Regional
(Andalusia)
15 476 24 30-day
all-cause (crude)
Rodriguez-Bano [19]
Spain 2003–2004 Multicentre, prospective,
observational
Academic
medical
centres
3 576 27.3 30-day
all-cause (crude)
Valles [20]
RAISIN, Reseau d’alerte d’investigation et de surveillance des infections nosocomiales (a national programme for early warning, investigation and surveillance of healthcare-
associated infection in France).
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(Surveillance of hospital-acquired bacteraemia in English
hospitals 1997–2002 (http://www.hpa.org.uk), accessed 22
October 2012). From 102 participating National Health
Service hospitals in England, the study collected data on
nearly 3 million hospital admissions. A total of 10 871
episodes of nosocomial BSI were found, with incidence rates
of 3.5 episodes per 1000 hospital admissions and 0.6
episodes per 1000 patient-days. On the basis of nearly
11 million hospital discharges annually in England [2],
we estimated approximately 39 000 episodes of nosocomial
BSI with 4700–12 500 deaths per year, assuming a CFR of
12–32%.
From 1999 to 2000, a surveillance project on nosocomial
BSI was performed in southern Finland [15]. The study
reported incidence rates of nosocomial BSI of 0.8 per 1000
patient-days and 2.7 per 1000 hospital admissions. When we
applied these rates to the entire population of Finland of
5.2 million and annual hospital discharges of 1.3 million in 2000
[2], we estimated approximately 3500 episodes of nosocomial
BSI per year. The same surveillance study reported a 30-day
CFR of 16% following nosocomial BSI [15]. Accordingly, we
estimated approximately 560 deaths from nosocomial BSI per
year in Finland.
More recently, the Andalusian Society of Infectious Diseases
conducted a prospective cohort study of BSI in Spain from
2006 to 2007 [19]. Over 5 months of the survey period, the
study enrolled 476 episodes of nosocomial BSI. Interestingly,
the incidence rate of nosocomial BSI was 8.4 episodes per
1000 hospital admissions (1.3 episodes per 1000 patient-days),
which was significantly higher than previously reported
incidence rates of nosocomial BSI from other geographical
areas in Europe. When this incidence rate was applied to the
entire nation of Spain with over 4.8 million annual hospital
discharges in 2007 [2], we estimated approximately 40 000
episodes of nosocomial BSI per year and 9700–11 000 deaths,
assuming a CFR of 24–27% [19,20].
Discussion
In this systematic review, we estimate nearly 2 million
episodes and one-quarter of a million deaths from BSI annually
in North America and Europe combined. As the incidence rate
of BSI increases with age [4], the burden of BSI will probably
increase over the next decade, owing to the increase in life-
expectancy in the populations of most industrialized countries,
including the USA [1]. As the population of North America and
Europe constitutes only one-seventh of the entire world
population (World Bank (http://www.worldbank.org),
accessed 29 January 2013), it is conceivable that the annual
number of deaths from BSI may be comparable to the number
caused by the three big infectious disease killers in the world:
human immunodeficiency virus (1.8 million deaths in 2010),
tuberculosis (1.4 million deaths in 2011), and malaria (660 000
deaths in 2010) (WHO (www.who.int), accessed 29 January
2013). With the advancement of science and research in
China, India, and Brazil, it would be interesting to see
population-based studies that estimate the incidence rates of
BSI in these large nations.
As hypothesized, data from ICD codes severely underes-
timate the burden of BSI. For example, it has been estimated
that 36 000 deaths occur per year in the USA from BSI/
septicaemia, according to ICD codes [1]. However, popula-
tion-based data from Olmsted County, Minnesota indicate
nearly double that number (72 000–79 000 deaths per year).
This is probably a conservative estimate, as the incidence rate
of BSI is probably higher in other geographical areas in the USA
where intravenous drug use is more prevalent than in Olmsted
County, Minnesota [21].
Our estimates suggest that BSI is among the top seven
causes of death in many European and North American
countries. Estimates of a BSI mortality rate of 23.5–27.5 per
100 000 person-years in the USA indicate that BSI contributes
TABLE 5. Burden of nosocomial bloodstream infection (BSI) in North America and Europe as estimated from surveillance
studies of nosocomial infections
Country
Time
period
Incidence
rate of
nosocomial
BSI (per 1000
patient-days)
Incidence
rate of
nosocomial
BSI (per 1000
hospital
admissions)
Nationwide epidemiology
Population
(in millions)
Annual number
of hospital
discharges
(in millions)
Estimated
number of
episodes of
nosocomial BSI
Case-fatality
rate following
nosocomial
BSI (%)
Estimated
number of
deaths following
nosocomial BSI
USA 1995–2002 0.8 6.0 287.6 37.8 226 800 15–30 34 020–68 040
France 2004 0.45 2.7a 62.7 16.8 45 360 12 5443
England 1997–2002 0.6 3.5 49.6 11.1 38 850 12–32b 4662–12 432
Finland 1999–2000 0.8 2.7 5.2 1.3 3510 16 562
Spain 2006–2007 1.3a 8.4 45.2 4.8 40 320 24–27 9677–11 007
aIncidence rates are estimated on the basis of average length of hospital stay in each country.
bCase-fatality rates are estimated from studies of nosocomial BSI in other European countries.
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to more deaths than any other infection, including influenza
and pneumonia combined (16.2 per 100 000 population in
2010), diabetes mellitus (22.4 per 100 000), heart failure (18.7
per 100 000), kidney disease (16.3 per 100 000), chronic liver
disease (10.3 per 100 000), suicide (12.4 per 100 000), motor
vehicle accidents (11.4 per 100 000), colorectal cancer (17.0
per 100 000), breast cancer (13.3 per 100 000), prostate
cancer (9.3 per 100 000), or cancer of any individual solid
organ, with the exception of the lungs. The mortality rate of
BSI is comparable to that of Alzheimer’s disease (27.0 per
100 000), the sixth leading cause of death in the USA in 2010
(CDC (www.cdc.gov), accessed 31 January 2013). Obviously,
BSI has not received as much attention as many of the above
diseases, which have less impact on the morbidity and
mortality of the general population. This highlights the need
for more organized efforts to facilitate basic, translational and
clinical research in this field that could lead to a better
understanding of the pathophysiology and improvement of the
outcome of BSI. Despite the decline in the CFR following BSI
over the past two decades [6], which is mostly attributable to
advances in critical care and antimicrobial management, there
is still much room for improvement. It is alarming that 30% of
patients with BSI receive inappropriate empirical antimicrobial
therapy [10], which is independently associated with poor
outcome [6,22]. This also emphasizes the need for national
guidelines for the management of BSI. Such guidelines should
have as much emphasis on de-escalation of antimicrobial
therapy as on optimizing empirical therapy.
This review also highlights the difficulty in obtaining precise
estimates of the burden of BSI in the developed world,
particularly in the USA, where only one population-based
study of the overall incidence rate of BSI was conducted
during the past decade [4]. Generalizing the results from the
relatively small population of Olmsted County (124 000) to
the entire USA population of >300 million may not be
optimal, given some differences in population characteristics
[21]. However, the incidence rate in Olmsted County
was similar to that reported from other developed countries
[10–12].
It is interesting to see a difference in the reported CFR of BSI
in population-based studies from North America and Europe
(range: 13–21%). Some of this difference may be explained by
the different methods used. Our previous work has demon-
strated that the in-hospital CFR underestimates the number of
deaths as compared with the 28-day or 30-day CFR, as some
patients may die at home or in nursing hospices soon after
discharge from the hospital (M. N. Al-Hasan, L. M. Baddour,
Unpublished). Although all-cause, non-attributable mortality
was used to estimate the number of deaths, BSI was certainly a
contributory factor to deaths occurring shortly after BSI.
Additionally, exclusion of all potential skin contaminants in
blood cultures, such as coagulase-negative staphylococci and
Corynebacterium species, without clinical verification may falsely
lower the incidence rate of BSI and increase the overall CFR, as
BSI caused by these low-virulence organisms is associated with
a favourable outcome. Finally, it remains possible that this
difference in CFR may be a result of different proportions of
patients receiving inadequate empirical antimicrobial therapy,
as these data have not been reported in most studies.
Nosocomial BSI has particular importance from the public
health standpoint. Optimizing the management and empirical
antimicrobial therapy may reduce the burden of nosocomial
BSI, but prevention is the key element. Many cases of
nosocomial BSI are potentially preventable with proper access
techniques and earlier discontinuation of central venous and
urinary catheters in hospitalized patients.
We used two different methods in this review to estimate
the burden of nosocomial BSI: estimates from population-
based studies, and nosocomial infection surveillance systems.
The difference in the results between the two methods was
substantial. For example, we estimated 102 000–120 00
episodes of nosocomial BSI per year in the USA, using data
from population-based studies, and 227 000 episodes using
nosocomial infection surveillance systems. Estimates of noso-
comial BSI in England and Finland also demonstrated the same
pattern; higher estimates from nosocomial infection surveil-
lance systems than from population-based studies. We believe
that nosocomial infection surveillance systems overestimate
the burden of nosocomial BSI, probably because of referral
bias. Despite efforts to include a diverse sample of hospitals in
such surveillance systems, most participating institutions
remain tertiary-care hospitals that receive referrals of patients
with very complex or advanced diseases, which probably
increases the risk of complications, including nosocomial BSI.
In addition, the participating centres in such surveillance
studies are not randomly selected, and therefore do not fairly
represent the entire country. Estimates from population-based
studies are probably more accurate, owing to lack of referral
bias [23]. In addition, the overall incidence rates of BSI
reported from population-based studies were similar between
the four countries where such data were directly provided
(the USA, Denmark, Finland, and England), with only a 12%
difference between the highest and lowest incidence rates of
189 and 166 per 100 000 person-years, respectively [4,10–12].
In contrast, the difference in incidence rates of nosocomial BSI
reported from nosocomial infection surveillance systems in
different countries was substantial. The 65% difference
between the highest and lowest incidence rates of 1.3 and
0.45 per 1000 patient-days, respectively, is unlikely to be
explained by a temporal change in incidence rate over a
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relatively short period of time (Table 5). Additionally, there
were wide variations in the number of hospital discharges per
1000 population between different countries, probably
because of differences in the structure of the healthcare
systems between the countries. This has substantially influ-
enced the estimates of nosocomial BSI obtained with nosoco-
mial surveillance systems. Moreover, the difference in the CFR
of nosocomial BSI between studies was also substantial (range:
12–32%). This was probably caused by differences in the
methods used to report the CFR (7 days vs. 30 days vs. in-
hospital) and differences in the complexity of cases and other
host-related factors that influenced the outcome of hospital-
ized patients.
This further emphasizes the importance of population-based
studies in estimating the burden of not only community-onset
BSI, but also nosocomial BSI. Population-based studies using
laboratory surveillance of BSI with clinical validation and
consistent exclusion criteria for potential skin contaminants in
blood cultures, preferably from multiple geographical locations
in the same country or the entire nation, if feasible, would yield
very informative data. In addition to demographics and site of
infection acquisition, it would be beneficial to report other
variables that are independently associated with mortality, in
order to allow meaningful comparison across different
geographical areas. These include acute severity of illness as
indicated by the Pitt bacteraemia score [24], receipt of
adequate antimicrobial regimens [22], primary source of
infection, and the presence or absence of malignancy and liver
cirrhosis [25]. Recently, a major step has been taken in the
right direction with the development of a multinational
population-based BSI surveillance collaboration between six
geographical regions in four countries and three continents
[26]. We are hoping that such collaboration will generate
large-scale data regarding the epidemiology, temporal trends
and outcome of BSI, and encourage other nations to follow
this direction by investing in high-quality research in popula-
tion-based settings.
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